Swedish biotech lands $4m for non-drug approach to obesity and diabetes

Swedish biotech lands $4m for non-drug approach to obesity and diabetes

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Sigrid Therapeutics deploys micron-sized silica particles to prevent digestive enzymes from breaking down carbohydrates and fats.

Funding continues to flow for companies targeting obesity, with Swedish biotech Sigrid Therapeutics revealing it has raised $4 million in an oversubscribed funding round. The company’s SiPore technology is a natural, non-drug alternative designed to address obesity and diabetes.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 3578

Sigrid Therapeutics

Longevity level(s):

  • Level 5: Aging disease management
    Therapeutic interventions that manage the symptoms of diagnosed aging diseases (i.e. current mainstream healthcare) and biotechnology companies focused on developing drugs to treat age-related diseases.

Overview

Sigrid Therapeutics is a Swedish medtech and consumer health company pioneering non-pharmaceutical approaches to metabolic disease management. The company develops and commercializes products based on its proprietary SiPore® technology, a precisely engineered silica-based platform that operates mechanically in the gastrointestinal tract without systemic absorption. Its portfolio includes Glucose Stabiliser and Carb Fence, designed to support blood glucose regulation and weight management in individuals with prediabetes, type 2 diabetes, and obesity. The company's mission centers on translating over 15 years of materials science research into accessible, clinically validated solutions for preventing and treating lifestyle-related metabolic disorders.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE